Longeveron Inc. (NASDAQ:LGVN) Q1 2023 Earnings Conference Call May 12, 2023 8:30 AM ET

Company Participants

James Clavijo - Chief Financial Officer

Wa'el Hashad - Chief Executive Officer

Chris Min - Acting Chief Medical Officer & Consultant

Conference Call Participants

Michael Okunewitch - Maxim Group

Operator

Good morning, and welcome to Longeveron's call today to discuss the company's 2023 First Quarter and Financial Results. All participants are currently in listen-only mode. Following the formal presentation, we will open the call up for a question-and-answer session.

I would now like to turn the conference over to James Clavijo, Chief Financial Officer of Longeveron. James, you may now proceed.

James Clavijo

Thank you, operator. Good morning, everyone, and welcome to Longeveron's first quarter 2023 Call. Today, we will provide a business update and discuss financial results for the first quarter of 2023. Earlier this morning, we issued a press release with these results, which can be found under the Investors section of our website at www.longeveron.com.

I am joined on the call today by the following members of Longeveron's management team; Mr. Wa’el Hashad, Chief Executive Officer; Dr. Joshua Hare, Co-Founder, Chief Scientific Officer and Chairman; and Dr. Chris Min, Acting Chief Medical Officer and Consultant to Longeveron. Mr. Hashad will begin with a brief statement and corporate overview, then Dr. Min will provide a review of updates from Longeveron's clinical programs in Hypoplastic Left Heart Syndrome or HLHS, Alzheimer's disease and aging-related frailty, after which I will review our 2023 first quarter financial results. Last, we will open the call for Q&A

As a reminder, during this call, we will be making forward-looking statements, which are subject to various risks and uncertainties that could cause our actual results to differ materially from these statements. Any such statements should be considered in conjunction with cautionary statements in our press releases and risk factors discussions in our filings with the SEC, including our annual report on Form 10-K and cautionary statements made during this call. We assume no obligation to update any of these forward-looking statements or information.

Now, I'd like to turn the call over to Mr. Wa’el Hashad, Chief Executive Officer of Longeveron. Wa’el?

Wa'el Hashad

Thank you, James. Good morning, everyone. Welcome to Longeveron first quarter 2023 business update and financial results call. Longeveron is a clinical stage biotechnology company, developing regenerative medicine for unmet medical needs.

Our lead investigational product called Lomecel-B is a living cell product made from a specialized cells isolate from the bone marrow of young healthy adult donor aged 18 to 45. These specialized cells are known in the literature as medicinal signaling cells or MSC, and are essential to our endogenous or built-in repair mechanism.